Cormorant Asset Management, LP Zymeworks Inc. Transaction History

Cormorant Asset Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$6.0 - $16.98 $3.6 Million - $10.2 Million	-600,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.19 - $29.33 $5.32 Million - $10.3 Million	-350,000 Reduced 36.84%	600,000 $9.83 Million
Q3 2021 Nov 15, 2021	SELL	$27.35 - $37.28 $10.2 Million - $13.9 Million	-371,936 Reduced 28.14%	950,000 $27.6 Million
Q2 2021 Aug 16, 2021	SELL	$26.5 - $38.23 $18 Million - $25.9 Million	-678,064 Reduced 33.9%	1,321,936 $45.9 Million
Q1 2021 May 17, 2021	BUY	$29.83 - $56.81 $23.9 Million - $45.4 Million	800,000 Added 66.67%	2,000,000 $63.2 Million

Q4 2020 Feb 16, 2021	BUY	$39.12 - $54.99 $1.96 Million - $2.75 Million	50,000 Added 4.35%	1,200,000 $56.7 Million
Q3 2020 Nov 16, 2020	BUY	$29.21 - $46.58 $17.5 Million - $27.9 Million	600,000 Added 109.09%	1,150,000 $53.6 Million
Q2 2020 Aug 14, 2020	SELL	$33.67 - $40.0 $5.05 Million - $6 Million	-150,000 Reduced 21.43%	550,000 $19.8 Million
Q4 2019 Feb 14, 2020	BUY	$24.84 - $45.46 $17.4 Million - $31.8 Million	700,000 New	700,000 $31.8 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $525M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.